---
title: Scaffold Novelty Fraction in Drug Design
url: https://www.emergentmind.com/topics/scaffold-novelty-fraction
type: topic
---

# Scaffold Novelty Fraction in Drug Design

The Scaffold Novelty Fraction ($F_{\mathrm{novel}}$) is a quantitative metric used to assess the ability of molecular generative models—particularly within the scaffold hopping paradigm of drug design—to propose new chemical frameworks not previously encountered in the training data. Scaffold hopping aims to identify novel core structures (Bemis–Murcko scaffolds) that preserve essential ligand features and functional-group geometry, thereby enabling the exploration of new chemical spaces for improved potency, selectivity, or physicochemical properties. $F_{\mathrm{novel}}$ provides a rigorous measurement of a model’s capacity to generate such unprecedented molecular backbones, and has become an essential benchmark in the evaluation of scaffold-centric generative algorithms [2308.07416].

## 1. Formal Definition and Mathematical Formulation

Let $\mathcal{D}_{\text{train}}$ denote the set of ligands present in the training split of a molecular dataset (such as PDBBind). The Bemis–Murcko scaffold for a ligand $\ell$ is defined by the function $\operatorname{scaffold}(\ell) \in \mathcal{S}$, where $\mathcal{S}$ denotes the universe of possible Murcko scaffolds as computable via cheminformatics tools such as RDKit. Define:
- $S_{\text{train}} = \left\{ \operatorname{scaffold}(\ell) \mid \ell \in \mathcal{D}_{\text{train}} \right\}$: the reference set of training scaffolds.
- $S_{\text{gen}} = \left\{ \operatorname{scaffold}(\ell) \mid \ell \in \mathcal{G} \right\}$: the set of scaffolds extracted from generated molecules $\mathcal{G}$.

The Scaffold Novelty Fraction is:
$$
F_{\mathrm{novel}} = 
\frac{\left| S_{\text{gen}} \setminus S_{\text{train}} \right|}{\left| S_{\text{gen}} \right|}
$$
This computes the fraction of unique Murcko scaffolds among the generated molecules that are not exact matches to any scaffold in the training set.

## 2. Computation Protocol

The canonical workflow for determining $F_{\mathrm{novel}}$ proceeds as follows. First, all Bemis–Murcko scaffolds from both the training ligands and generated molecules are extracted. Novelty is defined stringently; a scaffold is considered novel only if its molecular framework SMILES string does not appear anywhere in $S_{\text{train}}$. No size, similarity, or fuzzy-matching threshold is applied—exact substructure mismatch is required. For each model or baseline, generation is typically performed for $N$ candidate molecules per test protein pocket (e.g., $N=10$ in the DiffHopp protocol), and $F_{\mathrm{novel}}$ is computed over these unique scaffolds [2308.07416].

## 3. Empirical Performance in Contemporary Generative Models

The Scaffold Novelty Fraction has been benchmarked in conditional diffusion and inpainting models for scaffold hopping. The following table presents the mean and standard deviation values ("Novelty" in Table 1 of the source) across tested architectures:

| Method                  | Novelty ($F_{\mathrm{novel}}$)   |
|-------------------------|------------------------------|
| DiffHopp (GVP-denoiser) | 0.998 ± 0.05                 |
| DiffHopp-EGNN           | 1.000 ± 0.02                 |
| GVP-inpainting          | 0.997 ± 0.06                 |
| EGNN-inpainting         | 0.999 ± 0.03                 |
| Test-set ligands        | 1.000 ± 0.00                 |

All generative strategies evaluated produce almost entirely novel scaffolds ($\approx 99.7$–$100\%$). DiffHopp matches or slightly exceeds general inpainting pipelines in terms of $F_{\mathrm{novel}}$ [2308.07416].

## 4. Relationship to Chemical Diversity, Potency, and Quality

A high $F_{\mathrm{novel}}$ verifies that diffusion-based molecular generators can traverse chemical space and propose unseen core frameworks. Empirical data indicate that DiffHopp’s near-perfect novelty fraction ($0.998$) is obtained in tandem with robust binding affinity (mean Vina score $\approx -7.88$ kcal/mol) and drug-likeness (QED $\approx 0.61$). This suggests that enforced scaffold novelty does not detract from potency or lead-like properties. Other quality measures such as connectivity, synthetic accessibility, and molecular metrics remain critical for assessing the holistic value of generated molecules; DiffHopp exhibits superior connectivity (0.91) compared to inpainting methods (0.65–0.79), signifying better structural integrity and protein pocket complementarity [2308.07416].

## 5. Benchmarking, Limitations, and Statistical Considerations

The reporting of $F_{\mathrm{novel}}$ typically involves mean and standard deviation calculations over multiple runs or test protein pockets. No formal hypothesis tests, $p$-values, or bootstrapped confidence intervals have been applied to novelty comparisons in the referenced evaluations. Given the uniformity of near-unity results, the metric does not currently discriminate meaningfully between state-of-the-art models. A plausible implication is that scaffold novelty is largely a solved problem for contemporary graph diffusion and inpainting pipelines, and further benchmarking emphasis has shifted to other axes such as synthetic tractability or pharmacophoric coverage [2308.07416].

## 6. Practical and Intellectual Property Implications

Innovating on molecular scaffolds is crucial for patentability and the pursuit of novel intellectual property in drug discovery. High $F_{\mathrm{novel}}$ values confirm that generative models like DiffHopp can efficiently deliver new scaffolds while conserving the three-dimensional arrangement of functional groups relative to the protein pocket. This capability supports the practical translation of generative design into projects prioritizing chemical novelty, patentability, and lead optimization [2308.07416].

## 7. Comparative Role in Scaffold Hopping Methodologies

While inpainting-based and diffusion-based generative approaches both achieve $F_{\mathrm{novel}} \approx 0.997$–$1.000$, the explicit conditioning and loss functions in models like DiffHopp yield improved connectivity and affinity metrics. This suggests that task-specific model architectures targeting scaffold hopping offer advantages over generalist generative frameworks, particularly when empirical performance on secondary medicinal chemistry metrics is factored alongside scaffold novelty [2308.07416].

Source: https://www.emergentmind.com/topics/scaffold-novelty-fraction